Press Release: Unprecedented progression-free survival benefit with afatinib* associated with clinically meaningful improvements in life-limiting lung cancer symptoms and better quality of life
28.09.2012New data from the LUX-Lung 3 trial in first-line patients with EGFR mutation positive NSCLC, presented at the ESMO 2012 Congress (European Society for Medical Oncology) shows that patients benefit from substantial improvements in lung cancer-related symptoms and have better quality of life when treated with the irreversible ErbB Family Blocker, afatinib*.
Presentation: Sunday, September 30; 12:45 - 2:45 PM CEST
Poster Discussion Session: NSCLC, metastatic
Vienna, Austria, 28 September 2012 - Data from LUX-Lung 3, the largest and most robust registration trial to datea in patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC) shows that the novel compound afatinib*, an irreversible ErbB Family Blocker, leads to better and longer control and improvement of the most common lung cancer-related symptoms and better quality of life (QoL) compared to chemotherapy (pemetrexed and cisplatin), considered best-in-class for non-squamous NSCLC.1,2 These findings further reinforce the outstanding first-line efficacy of afatinib* in patients with EGFR mutation positive NSCLC.
*These are investigational compounds.
Their safety and efficacy have not yet been fully established.
a LUX-Lung 3 included 345 patients in 133 sites in 25 countries. Results were independently reviewed. The chemotherapy arm was cisplatin / pemetrexed, considered the most efficacious platinum doublet chemotherapy in advanced and metastatic lung cancer.2 The trial prospectively selected EGFR (ErbB1) mutations, rather than retrospectively. The trial was the largest trial conducted in lung cancer patients with EGFR mutations. The trial included patients from all over the world including Caucasians and Asians.